Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin SSD for the Delay of Encephalopathy Decompensation in Cirrhosis
NCT05297448Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of rifaximin in hepatic encephalopathy (HE), sponsored by Valeant Pharmaceuticals. Started Aug 2022; status: completed.
02
Drugs
rifaximin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT05297448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297448.